Your browser doesn't support javascript.
loading
Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis.
Sun, Xiaoduan; Wei, Jun; Lyu, Jiayao; Bian, Tierong; Liu, Zhongbing; Huang, Juan; Pi, Fengjuan; Li, Chunhong; Zhong, Zhirong.
Afiliación
  • Sun X; Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Wei J; Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Lyu J; Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Bian T; Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Liu Z; Medical Experimental Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Huang J; Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China.
  • Pi F; Luzhou TCM Hospital, Luzhou, 646000, Sichuan, China.
  • Li C; Luzhou TCM Hospital, Luzhou, 646000, Sichuan, China.
  • Zhong Z; Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, Sichuan, China. lispringhong@126.com.
J Nanobiotechnology ; 17(1): 10, 2019 Jan 22.
Article en En | MEDLINE | ID: mdl-30670021
BACKGROUND: Osteoporosis is a bone-incapacitating malady and it is characterized by obvious bone mass loss and bone microarchitecture deterioration. Current treatments for osteoporosis have many limitations, including the non-obvious therapeutic effect and long-term safety issues. Icariin is a pharmacologically active flavonoid glycoside, which shows potential application in treatment of osteoporosis. But its clinical application is limited by the inherent disadvantages such as poor water solubility, first pass effect after oral administration, and low bioavailability. Moreover, due to lack of targeting ability, icariin cannot accumulate at the local diseased region to provide early protection from fractures. To solve the application problems of icariin and enhance its therapeutic effects on osteoporosis, this work aimed to design a targeting drug delivery system of biomineral-binding liposomes (BBL) mediated by pyrophosphate ions. RESULTS: Biomineral-binding liposomes enhanced the binding ability of liposomes with hydroxyapatite particles. It increased the serum level of alkaline phosphatase and reduced that of tartrate-resistant acid phosphatase 5b. Meanwhile, BBL increased the mechanical strength of femoral midshaft, preserving the trabecular bone microarchitecture. Moreover, BBL could initiate bone turnover/remodeling of rats with osteoporosis. CONCLUSIONS: This drug targeting delivery system of BBL loading with icariin showed more therapeutic advantages than the free icariin for the treatment of osteoporosis, which may be a kind of valid candidate in future osteoporosis therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis / Flavonoides / Sistemas de Liberación de Medicamentos / Durapatita Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis / Flavonoides / Sistemas de Liberación de Medicamentos / Durapatita Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido